Subscribe

Vext Science, Inc. (VEXTF)

USD0.18 +0.00 (+0.97%)
US OTC Healthcare Drug Manufacturers - Specialty & Generic
Address 4152 North 39th Avenue 85019
Phoenix, AZ, US
CEO Eric J. Offenberger
Website vextscience.com
IPO 2019-05-28
ISIN CA9255401064

Explore sections of this company profile

Also trades on Canadian Securities Exchange · VEXT.CN (CAD) Other OTC · VEXTF (USD)
Description

Vext Science, Inc. operates as a comprehensive enterprise within the United States' cannabis sector, encompassing agricultural technology, various services, and property management. The company is actively involved in cultivating, extracting, manufacturing, and distributing a range of THC and CBD products, including vape cartridges, concentrates, and edibles. Beyond production, it also manages retail dispensaries and handles the wholesale distribution of cannabis-derived THC and hemp-derived CBD products, marketed under its Vapen and Pure Touch Botanicals brands. Furthermore, its Vapen Kitchens line offers a diverse selection of infused edibles, such as Vapen clear products, THC chocolate bars, syrups, snacks, and various candies, including gummies. Established in 2015, the company was formerly known as Vapen MJ Ventures Corporation until it rebranded to Vext Science, Inc. in November 2019, with its headquarters situated in Phoenix, Arizona.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
USD0.18 +0.00 (+0.97%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
32.2K
Beta
0.76
Float Shares
247.68M
Free Float %
100.0%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-4.94% -4.94% -3.16% +5.60% +5.48% +2.26% +111.20% -6.27% -73.91% -86.44% -86.44%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
0.18
Ratings Trend (MoM) 100% Bullish
Rating 2026-05 Change
Strong Buy 0 0
Buy 2 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
0.55
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    +45.2% ★ Q1'26: +3.7% (vs Q1'25)
  • ✗
    EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    +20.5% ★ Q1'26: +74.1% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    +7.1% Q1'26: +9.8% (vs Q1'25)
  • ✗
    EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    -17.9% Q1'26: -13.4% (vs Q1'25)
  • ✗
    ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    -11.0% Q1'26: -7.7% (vs Q1'25)
  • ✗
    Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    +2.8% Q1'26: +0.1% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    5.14× Q1'26: 3.68× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (1.07) × ERP
WACC = 58% × Ke + 42% × Kd (14.4%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 0.18
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
2 Rev. Ana.
2 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana.
Revenue
25.19M
est: 25.20M (0.0%)
37.24M
est: 37.37M (-0.3%)
35.41M
est: 35.51M (-0.3%)
34.81M
est: 37.05M (-6.0%)
36.00M
est: 35.80M (+0.5%)
52.27M
est: 51.75M (+1.0%)
57.20M
56.66M – 57.73M
+10.5% YoY
68.95M
67.80M – 70.09M
+20.5% YoY
74.00M
73.31M – 74.69M
+7.3% YoY
EBITDA
5.52M
est: 7.21M (-23.4%)
12.80M
est: 10.68M (+19.8%)
15.03M
est: 10.15M (+48.0%)
17.36M
est: 10.59M (+63.8%)
-2.02M
est: 9.60M (-121.0%)
6.80M
est: 13.88M (-51.0%)
15.34M
15.19M – 15.48M
+10.5% YoY
18.49M
18.18M – 18.79M
+20.5% YoY
19.84M
19.66M – 20.03M
+7.3% YoY
EBIT
3.38M
est: 1.90M (+78.5%)
9.54M
est: 2.81M (+239.3%)
8.85M
est: 2.67M (+231.4%)
7.59M
est: 2.79M (+172.3%)
-17.20M
est: 482.0K (-3,667.9%)
-9.35M
est: 696.7K (-1,442.2%)
770.1K
762.9K – 777.3K
+10.5% YoY
928.3K
912.8K – 943.7K
+20.5% YoY
996.3K
987.0K – 1.01M
+7.3% YoY
Net Income
2.13M
est: 6.18M (-65.6%)
4.99M
est: 10.44M (-52.2%)
10.92M
est: 9.58M (+14.0%)
4.40M
est: -2.41M (+282.6%)
-22.44M
est: -13.80M (-62.5%)
-18.31M
est: -12.38M (-47.9%)
-4.95M
-5.01M – -4.89M
+60.0% YoY
2.48M
2.45M – 2.51M
+150.0% YoY
-2.48M
-2.51M – -2.45M
-200.0% YoY
SGA
5.10M
est: 6.80M (-25.0%)
5.77M
est: 10.09M (-42.8%)
9.82M
est: 9.58M (+2.5%)
13.84M
est: 10.00M (+38.4%)
11.42M
est: 9.81M (+16.4%)
11.67M
est: 14.19M (-17.7%)
15.68M
15.53M – 15.82M
+10.5% YoY
18.90M
18.58M – 19.21M
+20.5% YoY
20.28M
20.09M – 20.47M
+7.3% YoY
EPS
0.02
est: 0.03 (-6.0%)
0.04
est: 0.04 (-16.7%)
0.08
est: 0.04 (+90.0%)
0.03
est: -0.01 (+367.0%)
-0.09
est: -0.06 (-67.0%)
-0.07
est: -0.05 (-48.0%)
-0.02
-0.02 – -0.02
+60.0% YoY
0.01
0.01 – 0.01
+150.0% YoY
-0.01
-0.01 – -0.01
-200.0% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-22 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-05-21 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-05-20 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-05-19 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-05-18 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-05-14 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-05-13 C 2/5 1/5 1/5 1/5 1/5 1/5 5/5
2026-05-12 C 2/5 1/5 1/5 1/5 1/5 1/5 5/5
2026-05-11 C 2/5 1/5 1/5 1/5 1/5 1/5 5/5
2026-05-08 C 2/5 1/5 1/5 1/5 1/5 1/5 5/5
2026-05-07 C 2/5 1/5 1/5 1/5 1/5 1/5 5/5
2026-05-06 C 2/5 1/5 1/5 1/5 1/5 1/5 5/5
2026-05-05 C 2/5 1/5 1/5 1/5 1/5 1/5 5/5
2026-05-04 C 2/5 1/5 1/5 1/5 1/5 1/5 5/5
2026-05-01 C 2/5 1/5 1/5 1/5 1/5 1/5 5/5
2026-04-30 C 2/5 1/5 1/5 1/5 1/5 1/5 5/5
2026-04-29 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-04-28 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-04-27 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-04-24 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-04-23 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-04-22 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-04-21 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-04-20 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-04-17 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
17.97M
OE per share TTM
0.08
Owner's Yield
37.34%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
84.7%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 1 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 AdvisorShares Pure US Cannabis ETF MSOS 0.05% 498.8K 0.81%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-54.1K
Shares Outstanding
247.68M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Eric J. Offenberger Chief Executive Officer, Chief Operating Officer, President & Director 309.7K male
Trevor Smith Chief Financial Officer 180.4K male
Nalee Pham Company Secretary 141.5K —
Jason Thai Nguyen Founder & Director — male
Jonathan Ross Investor Relations Officer — —
Scott Everett General Counsel & Corporate Secretary — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - Specialty & Generic